Drug · CHEMBL46
ONDANSETRON
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ONDANSETRON. Drugs and targets, record CHEMBL46. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL46
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| HTR3A | 5-hydroxytryptamine receptor 3A | Serotonin 3a (5-HT3a) receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/3359 |
Source ChEMBL
Diseases34
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 34Source Open Targets
See all 34 diseasesTrials353
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02625181 | Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis | 27,034 | 2019-03-07 | ondansetron | Its name | ClinicalTrials.gov | |
| NCT01594749 | Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031) | Phase 3 | 1,015 | 2015-09-25 | ondansetron | Its name | ClinicalTrials.gov |
| NCT00601172 | A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting. | Phase 3 | 710 | 2018-01-17 | ondansetron | Its name | ClinicalTrials.gov |
| NCT01395901 | Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients | Phase 3 | 670 | 2014-07-30 | ondansetron | Its name | ClinicalTrials.gov |
| NCT01442376 | Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients | Phase 3 | 502 | 2014-07-28 | ondansetron | Its name | ClinicalTrials.gov |
| NCT01859715 | Emergency Department (ED) Drug Interaction in Emergency Department Patients | 502 | 2016-05-05 | ondansetron | Its name | ClinicalTrials.gov | |
| NCT01636947 | A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) | Phase 4 | 494 | 2015-07-30 | ondansetron | Its name | ClinicalTrials.gov |
| NCT01254877 | Ondansetron, Alcohol Use, and Alcohol-Related Symptoms In HIV+ Persons | Phase 2 | 357 | 2018-04-17 | ondansetron | Its name | ClinicalTrials.gov |
| NCT02246439 | BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis | Phase 3 | 330 | 2019-02-20 | ondansetron | Its name | ClinicalTrials.gov |
| NCT02456662 | Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline (SPARED) Trial | 319 | 2020-04-16 | ondansetron | Its name | ClinicalTrials.gov |
1 to 10 of 353
See all 353 trialsComparisons in its trials80
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Fosaprepitant Regimen vs Control Regimen: serious adverse events | 39 of 504 | 35 of 497 | 1,001 | NCT01594749 | Trial comparisons |
| Casopitant 90 mg vs Placebo: deaths from any cause | 4 of 355 | 5 of 352 | 707 | NCT00601172 | Trial comparisons |
| Casopitant 90 mg vs Placebo: serious adverse events | 26 of 355 | 23 of 352 | 707 | NCT00601172 | Trial comparisons |
| Palonosetron and Placebo to Ondansetron vs Ondansetron and Placebo to Palonosetron: serious adverse events | 4 of 331 | 11 of 330 | 661 | NCT01395901 | Trial comparisons |
| Aprepitant Regimen vs Control Regimen: serious adverse events | 25 of 242 | 16 of 248 | 490 | NCT01636947 | Trial comparisons |
| RHB-102 vs Placebo Oral Tablet: Number of Patients Receiving Rescue Antiemetic Therapy - ITT Population | 48 of 192 | 43 of 129 | 321 | NCT02246439 | Trial comparisons |
| RHB-102 vs Placebo Oral Tablet: Responders Through 4 Days After First Dose of Study Medication - ITT Population | 114 of 192 | 67 of 129 | 321 | NCT02246439 | Trial comparisons |
| RHB-102 vs Placebo Oral Tablet: Number of Patients Requiring Hospitalization - ITT Population | 11 of 192 | 3 of 129 | 321 | NCT02246439 | Trial comparisons |
| RHB-102 vs Placebo Oral Tablet: Number of Patients Receiving Intravenous Fluids - ITT Population | 34 of 192 | 32 of 129 | 321 | NCT02246439 | Trial comparisons |
| RHB-102 vs Placebo Oral Tablet: Treatment Success From 30 Minutes Through 24 Hours After First Dose of Study Medication - ITT Population (Logistic Regression Adjusted by Baseline Nausea Severity) | 126 of 192 | 70 of 129 | 321 | NCT02246439 | Trial comparisons |
1 to 10 of 80
See all 80 comparisons in its trialsPapers from its trials203
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Food Cue Reactivity Task | 1 | 1 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL46
GET https://conductscience.org/api/drugs/v1/CHEMBL46/diseases?page=2